The BST2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human lung adenocarcinoma A-549 cell line, designed for the disruption of the BST2 gene. This loss-of-function model enables investigation of BST2-mediated pathways without the interference of wild-type protein expression.
The parental A-549 cell line originates from a 58-year-old male with lung adenocarcinoma and exhibits adherent epithelial morphology with characteristics of alveolar type II pneumocytes. As a widely used model of human lung adenocarcinoma, A-549 cells provide a physiologically relevant context for studying tumor biology, inflammatory signaling, and host-pathogen interactions.
BST2, also known as tetherin, is an interferon-inducible antiviral restriction factor that tethers budding enveloped viruses to the cell membrane, preventing their release. Beyond its antiviral role, BST2 modulates NF-??B signaling by activating the IKK complex and promoting the nuclear translocation of NF-??B, leading to transcription of pro-inflammatory cytokines such as IL-6 and TNF-alpha. Upstream, BST2 expression is induced by type I and II interferons through the JAK-STAT pathway, involving IFNAR1/IFNAR2 receptors, JAK1, TYK2, STAT1, STAT2, and IRF9. Additionally, BST2 interacts with viral proteins such as HIV-1 Vpu, influenza A HA, and SARS-CoV-2 ORF7a, which counteract its tethering function, and with members of the ESCRT machinery, including TSG101 and VPS4, during viral budding.
In A-549 cells, knockout of BST2 abolishes interferon-induced restriction of enveloped virus release, making this model valuable for studying viral budding and host defense mechanisms. Simultaneously, loss of BST2 impairs NF-??B-mediated inflammatory signaling, potentially altering the expression of downstream cytokines and adhesion molecules. This dual disruption permits dissection of BST2??s role in both antiviral innate immunity and tumor-promoting inflammatory pathways, which is particularly relevant in the context of lung adenocarcinoma, where chronic inflammation and immune evasion contribute to cancer progression.
Researchers can employ these polyclonal knockout cells in a variety of assays, including viral release assays (e.g., HIV-1 budding), western blotting for BST2 and phosphorylated NF-??B, RT-qPCR for interferon-stimulated genes, flow cytometry for surface BST2, NF-??B reporter assays, and migration/invasion assays. They are also suitable for co-immunoprecipitation studies of viral protein interactions and for drug screening campaigns targeting BST2-related pathways. For further information or to discuss custom projects, please contact Ascent Research.
